# Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

> **NCT04343248** · PHASE3 · TERMINATED · sponsor: **Romark Laboratories L.C.** · enrollment: 190 (actual)

## Conditions studied

- COVID-19
- Viral Respiratory Illnesses

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Placebo
- **DIETARY_SUPPLEMENT:** Vitamin Super B-Complex

## Key facts

- **NCT ID:** NCT04343248
- **Lead sponsor:** Romark Laboratories L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-12
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-02-01
- **Target enrollment:** 190 (ACTUAL)
- **Why stopped:** Study recruitment was halted prematurely as widespread vaccination of the study population made completion infeasible.
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04343248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04343248, "Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04343248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*